I am posting this week’s regulatory update a day early since our office will be closed tomorrow for the holiday weekend.  Only one new molecular entity was approved this week, along with a couple of new indication approvals. The FDA approved Kevzara (sarilumab), a treatment of rheumatoid arthritis which was co-developed by Sanofi and Regeneron. […]